OncoMatch/Clinical Trials/NCT04987463
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Is NCT04987463 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Vigabatrin and Rapamycin for tuberous sclerosis complex.
Treatment: Vigabatrin · Rapamycin — The purpose of the study is to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with Tuberous Sclerosis Complex (TSC).
Check if I qualifyExtracted eligibility criteria
Prior therapy
No prior treatment (treatment-naive required)
Cannot have received: antiepileptic treatment
history of antiepileptic treatment
Cannot have received: mTOR inhibitor
history of treatment with mTOR (mammalian Target of Rapamycin) inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify